WO2004033722A3 - Genetic profiling and healthcare management: adme (absorption, distribution, metabolism & elimination) & toxicology related genes and probes - Google Patents
Genetic profiling and healthcare management: adme (absorption, distribution, metabolism & elimination) & toxicology related genes and probes Download PDFInfo
- Publication number
- WO2004033722A3 WO2004033722A3 PCT/GB2003/004051 GB0304051W WO2004033722A3 WO 2004033722 A3 WO2004033722 A3 WO 2004033722A3 GB 0304051 W GB0304051 W GB 0304051W WO 2004033722 A3 WO2004033722 A3 WO 2004033722A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- genes
- adme
- metabolism
- probes
- elimination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003269159A AU2003269159A1 (en) | 2002-09-23 | 2003-09-23 | Genetic profiling and healthcare management: adme (absorption, distribution, metabolism and elimination) and toxicology related genes and probes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0222042.4 | 2002-09-23 | ||
GBGB0222042.4A GB0222042D0 (en) | 2002-09-23 | 2002-09-23 | Genostics |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004033722A2 WO2004033722A2 (en) | 2004-04-22 |
WO2004033722A3 true WO2004033722A3 (en) | 2004-08-12 |
Family
ID=9944593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/004051 WO2004033722A2 (en) | 2002-09-23 | 2003-09-23 | Genetic profiling and healthcare management: adme (absorption, distribution, metabolism & elimination) & toxicology related genes and probes |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003269159A1 (en) |
GB (1) | GB0222042D0 (en) |
WO (1) | WO2004033722A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006027182A1 (en) * | 2004-09-06 | 2006-03-16 | Medizinische Hochschule Hannover | Methods and its kits based on ugt1a7 promoter polymorphism |
US8099298B2 (en) | 2007-02-14 | 2012-01-17 | Genelex, Inc | Genetic data analysis and database tools |
JP4410269B2 (en) | 2007-03-28 | 2010-02-03 | 株式会社東芝 | Nucleic acid primer set, kit for detecting genotype of N-acetyltransferase 2 (NAT2), and detection method using the primer set |
WO2009052559A1 (en) * | 2007-10-22 | 2009-04-30 | Melbourne Health | A diagnostic assay |
US7951542B2 (en) | 2009-11-04 | 2011-05-31 | Surgene, LLC | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US7951543B2 (en) | 2009-11-04 | 2011-05-31 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US7972793B2 (en) | 2009-11-04 | 2011-07-05 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US7985551B2 (en) | 2009-11-04 | 2011-07-26 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US10210312B2 (en) | 2013-02-03 | 2019-02-19 | Youscript Inc. | Systems and methods for quantification and presentation of medical risk arising from unknown factors |
CN109355368A (en) * | 2018-10-22 | 2019-02-19 | 江苏美因康生物科技有限公司 | A kind of kit and method of quick detection hypertension individuation medication gene pleiomorphism |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2339200A (en) * | 1998-06-06 | 2000-01-19 | Genostic Pharma Ltd | Genomic profiling of disease susceptibility |
-
2002
- 2002-09-23 GB GBGB0222042.4A patent/GB0222042D0/en not_active Ceased
-
2003
- 2003-09-23 AU AU2003269159A patent/AU2003269159A1/en not_active Abandoned
- 2003-09-23 WO PCT/GB2003/004051 patent/WO2004033722A2/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2339200A (en) * | 1998-06-06 | 2000-01-19 | Genostic Pharma Ltd | Genomic profiling of disease susceptibility |
Non-Patent Citations (13)
Title |
---|
BIGLER J ET AL: "CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.", CANCER RESEARCH. UNITED STATES 1 MAY 2001, vol. 61, no. 9, 1 May 2001 (2001-05-01), pages 3566 - 3569, XP002284193, ISSN: 0008-5472 * |
BULLETIN OF NATIONAL INSTITUTE OF HEALTH SCIENCES 1998 JAPAN, no. 116, 1998, pages 69 - 81, ISSN: 1343-4292 * |
BUTLER W J ET AL: "Metabolic genotypes and risk for colorectal cancer.", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. AUSTRALIA JUN 2001, vol. 16, no. 6, June 2001 (2001-06-01), pages 631 - 635, XP002284253, ISSN: 0815-9319 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; December 2001 (2001-12-01), RISCH ANGELA ET AL: "Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas", XP002284256, Database accession no. PREV200200096544 * |
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1998, OZAWA S: "Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes", XP002284255, Database accession no. EMB-1999021735 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 1998 (1998-02-01), YAMAZAKI H ET AL: "Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.", XP002284194, Database accession no. NLM9522436 * |
ERICKSON R P ET AL: "Genetic variation in beta-adrenergic receptors and their relationship to susceptibility for asthma and therapeutic response.", DRUG METABOLISM AND DISPOSITION: THE BIOLOGICAL FATE OF CHEMICALS. UNITED STATES APR 2001, vol. 29, no. 4 Pt 2, April 2001 (2001-04-01), pages 557 - 561, XP002284264, ISSN: 0090-9556 * |
EVANS WILLIAM E ET AL: "Pharmacogenomics: Translating functional genomics into rational therapeutics", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 286, no. 5439, 15 October 1999 (1999-10-15), pages 487 - 491, XP002193947, ISSN: 0036-8075 * |
INGELMAN-SUNDBERG M ET AL: "Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment", TRENDS IN PHARMACOLOGICAL SCIENCES 1999 UNITED KINGDOM, vol. 20, no. 8, 1999, pages 342 - 349, XP002284252, ISSN: 0165-6147 * |
MITRUNEN KATJA ET AL: "Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer", CANCER EPIDEMIOLOGY BIOMARKERS AND PREVENTION, vol. 10, no. 3, March 2001 (2001-03-01), pages 229 - 236, XP002284254, ISSN: 1055-9965 * |
PHARMACOGENETICS, vol. 11, no. 9, December 2001 (2001-12-01), pages 757 - 764, ISSN: 0960-314X * |
STEWARD D J ET AL: "GENETIC ASSOCIATION BETWEEN SENSITIVITY TO WARFARIN AND EXPRESSION OF CYP2C9*3", PHARMACOGENETICS, CHAPMAN & HALL, LONDON, GB, vol. 7, no. 5, October 1997 (1997-10-01), pages 361 - 367, XP000921131, ISSN: 0960-314X * |
XENOBIOTICA;THE FATE OF FOREIGN COMPOUNDS IN BIOLOGICAL SYSTEMS. ENGLAND FEB 1998, vol. 28, no. 2, February 1998 (1998-02-01), pages 103 - 115, ISSN: 0049-8254 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004033722A2 (en) | 2004-04-22 |
AU2003269159A8 (en) | 2004-05-04 |
AU2003269159A1 (en) | 2004-05-04 |
GB0222042D0 (en) | 2002-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brett et al. | Functional gene polymorphisms in aggressive and chronic periodontitis | |
Gullapalli et al. | Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics | |
van der Weide et al. | Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology | |
Denisova et al. | Frequent DPH3 promoter mutations in skin cancers | |
Papagerakis et al. | Premature stop codon in MMP20 causing amelogenesis imperfecta | |
Hamilton | The promise of psychiatric pharmacogenomics | |
Enoch et al. | ‘Young’oral fibroblasts are geno/phenotypically distinct | |
US20160068904A1 (en) | Methods of skin analysis and uses thereof | |
WO2004033722A3 (en) | Genetic profiling and healthcare management: adme (absorption, distribution, metabolism & elimination) & toxicology related genes and probes | |
Heilmann et al. | Evidence for a polygenic contribution to androgenetic alopecia | |
Knudsen et al. | Increased skewing of X chromosome inactivation with age in both blood and buccal cells | |
Perls | Centenarians who avoid dementia | |
Tammiste et al. | Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression | |
US20080275912A1 (en) | Computer-Assisted Means for Providing Personalised Healthcare Products | |
WO2003010336A3 (en) | Molecular markers for hepatocellular carcinoma | |
Gugatschka et al. | DNA repair gene ERCC2 polymorphisms and risk of squamous cell carcinoma of the head and neck | |
Limdi et al. | Influence of CYP2C9 genotype on warfarin dose among African–Americans and European–Americans | |
Oetjens et al. | Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records | |
EP2792754A1 (en) | Biomarkers for epilepsy | |
Nathan et al. | Germline variants in oculocutaneous albinism genes and predisposition to familial cutaneous melanoma | |
Ng et al. | Is Dupuytren’s disease really a ‘disease of the Vikings’? | |
Roederer et al. | Applying the genome to national drug formulary policy in the developing world | |
Ragoussis et al. | Affymetrix GeneChip® system: moving from research to the clinic | |
Pugach et al. | The use of mouse models to investigate shear bond strength in amelogenesis imperfecta | |
Loza et al. | Association of alcohol-metabolizing genes with alcoholism in a Mexican Indian (Otomi) population |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |